MD-2, Human, mAb 18H10

Quantity:
100 µg
Catalog #:
HM2245

Original supplier of innate immunity products since 1994.

Our commitment to quality: Read more!

Contact our support team for more product information.

Can't find your application for a product? Request a sample!

The monoclonal antibody 18H10 reacts with MD-2, an accessory molecule of the Toll-like receptor 4 (TLR4, CD284). TLRs belong to a family of proteins that specifically recognizes and senses microbial products. They are highly conserved throughout evolution and act as innate immune recognition receptors against many pathogens. TLR4 is a functional receptor for gram-negative bacterial lipopolysaccharides (LPS). TLR4 associates with MD-2 which is absolutely required for LPS-induced activation of TLR4. MD-2 exists as a cell surface protein in association with TLR4. It also exists as secreted forms consisting of MD-2 monomers and multimers (sMD-2). Circulating sMD-2 is mainly present as a doublet of ~20 and 25 kD, representing differentially glycosylated forms. Unlike TLR4, sMD-2 binds directly LPS without the need of soluble CD14 (sCD14). However, LPS-MD-2 interactions are increased when LPS is pretreated with CD14. Only monomeric sMD-2 is biologically active and able to associate with TLR4 and LPS. sMD-2 circulates in plasma of healthy individuals as a non-active, polymeric protein. In septic plasma, the total amount of sMD-2 was strongly elevated and contained both sMD-2 polymers and monomers. Soluble MD-2 is proposed to be an important mediator of organ inflammation during sepsis. During experimental human endotoxemia, the monomeric and total sMD-2 content in plasma increased with the kinetics of an acute phase protein. This parallels enhanced TLR4 costimulatory activity. In vitro studies revealed that sMD-2 release appears to be restricted to endothelial and dendritic cells. The monoclonal antibody 18H10 reacts with MD-2. However, it does not react with sMD-2. In addition, the monoclonal antibody 18H10 is able to inhibit bacterial binding to MD-2.
Specifications
Product type Monoclonal antibodies
Quantity 100 µg
Formulation 1 ml (100 µg/ml) 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin.
Application Flow cytometry, Functional studies
Use For flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, dilutions have to be made according to the amounts of MD-2 to be inactivated.
Immunogen TLR4/MD-2 expressing CHO cells/ chimeric TLR4/MD-2 fusion protein
Isotype Mouse IgG2b
Species Human
Alias Lymphocyte antigen 96, ESOP-1, LY96
References 1. Pugin, J et al; Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood 2004, 104: 4071
2. Daubeuf, B et al; TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 2007, 179: 6107
3. Elson, G et al; Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. Blood 2007, 109: 1574
4. Tissieres, P et al; Soluble MD-2 is an acute phase protein and an opsonin for Gram-negative bacteria. Blood 2008, 111: 2122
Storage and stability Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hbt is not responsible for any patent infringements that might result with the use or derivation of this product.
Disease Infectious diseases
Applications
Application: Flow cytometry, Functional studies
Use: For flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, dilutions have to be made according to the amounts of MD-2 to be inactivated.
References
References: 1. Pugin, J et al; Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood 2004, 104: 4071
2. Daubeuf, B et al; TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 2007, 179: 6107
3. Elson, G et al; Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. Blood 2007, 109: 1574
4. Tissieres, P et al; Soluble MD-2 is an acute phase protein and an opsonin for Gram-negative bacteria. Blood 2008, 111: 2122
CoA-TDS HM2200 - 2300
pdf
(Size: 0.24 MB)
Protocol